Invicro - Imaging and Pathology Services
9.7/10 Overall Rating
No Reviews Yet
61 Orders Completed
Boston, Massachusetts, US
Headquartered in Boston, MA, Invicro's mission is to improve the role and function of imaging in drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotechnology companies across all stages (preclinical to phase IV), imaging modalities and therapeutic areas, including neurology, oncology, and systemic and rare diseases.
Invicro’s CAP-accredited, CLIA-certified anatomical pathology lab offers a wide-range of pathology services including, multiplex immunohistochemistry/immunofluorescence, RNAScope® ISH, pathologist interpretation, data management, image analysis and Quanticell™, a proprietary nanoparticle-based immunohistochemistry detection technology. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant™ and iPACS®, as well as their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ.
As part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology, and genomics.
Biomarkers play a pivotal role in the discovery and development of tailored drugs spanning multiple therapeutic areas, including oncology, immuno-oncology, CNS, inflammation, immunology, and others. Once identified, biomarkers can help with patient stratification, predict efficacy and toxicity, and monitor treatment response. Invicro provides expertise to support biomarker studies using multiple modalities, including:
At Invicro, we offer a structured approach by offering fully customizable services to evaluate how a drug behaves in preclinical models to first-in-human (FIH) clinical studies. Our dedicated scientific teams offer end-to-end solutions to support your imaging and pathology needs to evaluate the following:
Biomarkers play a pivotal role in the discovery and development of tailored drugs spanning multiple therapeutic areas, including oncology, immuno-oncology, CNS, inflammation, immunology, and others. Once identified, biomarkers can help with patient stratification, predict efficacy and toxicity, and monitor treatment response. Invicro provides expertise to support biomarker studies using multiple modalities, including:
At Invicro, we offer a structured approach by offering fully customizable services to evaluate how a drug behaves in preclinical models to first-in-human (FIH) clinical studies. Our dedicated scientific teams offer end-to-end solutions to support your imaging and pathology needs to evaluate the following:
Invicro provides end-to-end translational research and clinical trial pathology services, including sample processing, embedding, sectioning, staining, imaging and pathologic evaluation by board-certified pathologists. We collaborate with sponsors to design studies that will provide biological insights needed to advance drug discovery and development efforts. From core histology and simple immunostains, to more complex and custom assays, we provide scientific, regulatory and operational expertise to support projects across all phases and therapeutic areas.
In addition to our routine immunohistochemistry and novel quantitative biomarker imaging solutions, Invicro provides multiple specialty stains to support your research efforts across multiple disease areas, including:
Immunofluorescence (IF) is a powerful tissue-based method used in translational research to interrogate biomarkers on a single tissue section. IF allows for the visualization of target antigens on the cellular and subcellular level with tissue morphology preserved in a wide-range of sample types, such as solid tumor biopsies, lymph nodes and others.
Our laboratories possess the scientific expertise to develop and run singleplex and multiplex IF assays across multiple therapeutic areas. From early-stage discovery to exploratory endpoint testing in clinical trials, our team is prepared to support all your project needs. We perform IF on xenograft tumor models, tissue microarrays (TMA), and a diverse population of human and non-human tissue samples.
With multiple laboratory locations and a CAP-accredited CLIA-certified site, we offer comprehensive tissue services to support projects with varying levels of complexity. Our laboratories are equipped with the most advanced equipment from Leica, Agilent Dako, Biocare Medical and Ventana to support your specific project needs.
Immunofluorescence (IF) is a powerful tissue-based method used in translational research to interrogate biomarkers on a single tissue section. IF allows for the visualization of target antigens on the cellular and subcellular level with tissue morphology preserved in a wide-range of sample types, such as solid tumor biopsies, lymph nodes and others.
Our laboratories possess the scientific expertise to develop and run multiplex IF assays across multiple therapeutic areas. From early-stage discovery to exploratory endpoint testing in clinical trials, our team is prepared to support all your project needs. We perform IF on xenograft tumor models, tissue microarrays (TMA), and a diverse population of human and non-human tissue samples.
With multiple laboratory locations and a CAP-accredited CLIA-certified site, we offer comprehensive tissue services to support projects with varying levels of complexity. Our laboratories are equipped with the most advanced equipment from Leica, Agilent Dako, Biocare Medical and Ventana to support your specific project needs.
Immunohistochemistry (IHC) is a powerful tissue-based method used both in research and clinical diagnostics to evaluate pathological conditions. IHC allows for the visualization of target antigens on the cellular and subcellular level with tissue morphology preserved in a wide-range of sample types, such as solid tumor biopsies, lymph nodes and others.
Our laboratories possess the scientific, regulatory, and operational expertise to develop and run chromogenic IHC assays across multiple therapeutic areas. From early-stage discovery to exploratory endpoint testing and companion diagnostic (CDx) development, our team is prepared to support all your project needs to accelerate your drug discovery and development efforts. We perform IHC on xenograft tumor models, tissue microarrays (TMA), and a diverse population of human and non-human tissue samples.
With multiple laboratory locations and a CAP-accredited CLIA-certified site, we offer comprehensive IHC services to support projects with varying levels of complexity. Our laboratories are equipped with the most advanced equipment from Leica, Agilent Dako, Biocare Medical and Ventana to support your specific project needs.
Immunohistochemistry (IHC) is a powerful tissue-based method used both in research and clinical diagnostics to evaluate pathological conditions. IHC allows for the visualization of target antigens on the cellular and subcellular level with tissue morphology preserved in a wide-range of sample types, such as solid tumor biopsies, lymph nodes and others.
Our laboratories possess the scientific, regulatory, and operational expertise to develop and run multiplex chromogenic IHC assays across multiple therapeutic areas. From early-stage discovery to exploratory endpoint testing and companion diagnostic (CDx) development, our team is prepared to support all your project needs to accelerate your drug discovery and development efforts. We perform IHC on xenograft tumor models, tissue microarrays (TMA), and a diverse population of human and non-human tissue samples.
With multiple laboratory locations and a CAP-accredited CLIA-certified site, we offer comprehensive IHC services to support projects with varying levels of complexity. Our laboratories are equipped with the most advanced equipment from Leica, Agilent Dako, Biocare Medical and Ventana to support your specific project needs.
The RNAScope® technology from Advanced Cell Diagnostics (ACD) is a novel in situ hybridization (ISH) assay used for the detection of target RNA transcripts. By using this assay, multiple gene targets can be visualized while maintaining tissue architecture. Moreover, multiplex assays that include multiple gene and protein targets can be developed. With multiple laboratory locations and a CAP-accredited CLIA-certified site, we provide end-to-end solutions, including assay design, automated staining protocol development on Leica Bond RX and image analysis services.
Tissue cross reactivity (TCR) testing is in important screening method used in drug development, whereby biological therapies (e.g. monoclonal antibodies) are evaluated for specific and non-specific binding in different tissue types. This is important to ensure the therapeutic candidate binds to the target epitope and minimize drug-related toxicity. At Invicro, we offer non-GLP immunohistochemistry-based TCR testing services, including assay development and validation, along with interpretation and reporting required by the FDA, EMA, and other federal agencies that handle new drug applications.
Slide digitization is a critical step in image curation, organization, and qualitative and quantitative image analysis applications, including pathologist interpretation and IHC protein expression analysis. With major technological advancements observed in digital slide scanning technologies, biological insights can be seamlessly extracted from tissue images. At Invicro, we provide whole slide imaging (WSI) with multispectral capabilities, including the 3D HISTECH P250, Leica Aperio AT2 Whole Slide Scanner, and Hamamatsu NanoZoomer S60. In addition, we offer comprehensive image analysis services using Visiopharm and other state-of-the-art software tools.
Computational and digital pathology is transforming the way biology is visualized by enabling the interrogation of different biomarkers across therapeutic areas. As a leading quantitative biomarker solutions provider, Invicro delivers precise measurements on the tissue level to support translational research and clinical trials.
Our dedicated Image Analysis team has expertise in oncology, immuno-oncology, neurology, inflammation, NAFLD/NASH, and rare diseases. By developing highly sophisticated, custom image analysis methods coupled with our scientist-to-scientist approach, where we work side-by-side with partners, Invicro rapidly extracts valuable insights from a wide-range of staining methods, including H&E, multiplex chromogenic and fluorescent IHC, and ACD RNAScope® ISH technologies.
Companion and complimentary diagnostics are precision medicine tools used to stratify patients and predict likelihood of a favorable response based on the expression of specific biomarkers. These tests are developed in parallel for a new drug during clinical trials. To commercialize a product, sponsors work with contract research organizations (CRO) and in vitro (IVD) diagnostic providers. While this process is challenging, our team partners with sponsors to develop and deploy a strategy that supports successful diagnostic product commercialization.
In drug discovery research, it is critical to conduct ADME/DMPK studies to evaluate the biological activity of a drug prior to advancing to clinical trials. By using a combination of in vitro assays and in vivo imaging, Invicro can evaluate how compounds behave in biological systems and understand toxicology, safety and efficacy. These solutions help with making go/no-go decisions on whether a drug should be advanced as a candidate and support with Investigational New Drug (IND) filings with regulatory agencies. Invicro provides in vitro and in vivo ADME/DMPK studies to support your drug discovery and development needs.
In vitro assays play an important role in understanding the key pillars of drug survival at the early stages of development. Invicro provides cell and tissue-based in vitro methods, including homogenate binding autoradiography, radioligand binding assays, FACS and ELISA to support early-stages of drug discovery programs. These methodologies are routinely used to understand:
Our scientific team provides a consultative scientific approach in study design, study execution and data analysis to de-risk the drug development process.
From small molecules to large biologics, preclinical in vivo imaging studies are crucial in drug discovery and development. Imaging studies allow for the characterization of multiple key parameters, such as biodistribution, pharmacokinetics, pharmacodynamics, and efficacy in small animals and non-human primates prior to the start of first-in-human studies. At Invicro, we provide a consultative scientific approach in study design and execution and offer the full spectrum of imaging modalities including:
2D and 3D autoradiography (ARG) is used to evaluate radiotracer distribution in whole animals and organs. This imaging technique is complimentary to in vivo nuclear imaging modalities. ARG allows for the detection, visualization and quantitation of tracers to support ADME studies and determine drug pharmacokinetics (PK) and drug penetration into specific targets. Our experienced team of research scientists possess the knowledge to design, run, analyze data and report results to provide the insights you need to accelerate your drug discovery programs.
Radiochemistry method development plays a pivotal role in the early-stages of study design and development. Our dedicated chemistry team provides comprehensive radiochemistry solutions spanning early discovery to GMP manufacturing to support clinical work.
With access to multiple state-of-the-art cyclotrons for production of short-lived isotopes, Invicro develops strategies to run imaging studies in small animals, non-human primates (NHP), and human subjects spanning multiple phases and therapeutic areas, including oncology, immuno-oncology, CNS, inflammation, and others. The Invicro chemistry team has expertise in radiolabeling a wide range of compounds, including:
From small animals and non-human primates to multicenter clinical trials, Invicro provides structural, functional, and molecular imaging services to support sponsors with their therapeutic pipeline development needs. At Invicro, we combine our scientific, project management, medical, and operational expertise with state-of-the-art technologies to deliver insights needed to move drug programs forward. Invicro’s highly trained Image Analysis team (50+ invidudals) provide advanced analytics using the most advanced tools, such as AmyloidIQ, TauIQ and DaTIQ. In addition, our clinical team of highly distinguished board-certified radiologists provide read analysis services following a broad range of read criterions. Our dedicated team have the expertise to design, execute, and manage studies across a wide-range of modalities including:
From small animals and non-human primates to multicenter clinical trials, Invicro provides structural, functional, and molecular imaging services to support sponsors with their therapeutic pipeline development needs. At Invicro, we combine our scientific, project management, medical, and operational expertise with state-of-the-art technologies to deliver insights needed to move drug programs forward. Invicro’s highly trained Image Analysis team (50+ invidudals) provide advanced analytics using the most advanced tools, such as AmyloidIQ, TauIQ and DaTIQ. In addition, our clinical team of highly distinguished board-certified radiologists provide read analysis services following a broad range of read criterions. Our dedicated team have the expertise to design, execute, and manage studies across a wide-range of modalities including:
From small animals and non-human primates to multicenter clinical trials, Invicro provides structural, functional, and molecular imaging services to support sponsors with their therapeutic pipeline development needs. At Invicro, we combine our scientific, medical, and operational expertise with state-of-the-art technologies to deliver insights needed to move drug programs forward. Invicro’s highly trained Image Analysis team (50+ invidudals) provide advanced analytics using the most advanced tools, such as AmyloidIQ, TauIQ and DaTIQ. In addition, our clinical team of highly distinguished board-certified radiologists provide read analysis services following a broad range of read criterions. Our dedicated team have the expertise to design, execute, and manage studies across a wide-range of modalities including:
Positron emission tomography (PET) is a powerful modality used in molecular imaging for drug discovery and development applications. This Radionuclide-based imaging technique can be used to measure multiple readouts, including, pharmacokinetics and biodistribution to support sponsors with their drug development research. At Invicro, our dedicated team of research scientists provide comprehensive support for a wide-range of molecular imaging studies. Our services include, study design, image acquisition, data analysis, and interpretation.
Single photon-emission computed tomography (SPECT) is a powerful modality used in molecular imaging for drug discovery and development applications. This Radionuclide-based imaging technique can be used to measure multiple readouts, including, pharmacokinetics and biodistribution to support sponsors with their drug development research. At Invicro, our dedicated team of research scientists provide comprehensive support for a wide-range of molecular imaging studies. Our services include, study design, image acquisition, data analysis, and interpretation.
IVIS bioluminescence imaging (BLI) using luciferase reporters and IVIS fluorescence imaging has revolutionized discovery research and is now a mainstay for in vivo testing. These optical imaging approaches can be used to assess tumor burden in orthotopic and metastatic tumor models. Moreover, they can be used for evaluating gene therapies delivered using lipid nanoparticles, viruses, and siRNA along with cell tracking and transgenic applications. Through strategic partnerships, Invicro can assist with identifying tumor models needed to run optical imaging studies. Our services include, study design, image acquisition, data analysis, and interpretation.
To augment optical imaging, Invicro offers cryofluorescence tomography (CFT) as a preclinical drug discovery service. This 3D tissue imaging technique provide a high resolution and ultra-sensitive technique to visualize test articles, including AAV-based gene therapies, ASOs, antibodies (e.g., mAb), cells, and other biologics. This technology addresses some core challenges, including signal attenuation and the time needed to visualize certain biological events, such as gene transduction in targeted cells.
From small molecules to large biologics, preclinical in vivo imaging studies are crucial in drug discovery and development. Imaging studies allow for the characterization of multiple key parameters, such as biodistribution, pharmacokinetics, pharmacodynamics. At Invicro, we provide a consultative scientific approach in study design, imaging execution and data analysis in a wide-range of animal species, including:
From small molecules to large biologics, preclinical in vivo imaging studies are crucial in drug discovery and development. Imaging studies allow for the characterization of multiple key parameters, such as biodistribution, pharmacokinetics, pharmacodynamics. At Invicro, we provide a consultative scientific approach in study design, imaging execution and data analysis in a wide-range of animal species, including:
At Invicro, we offer single slice and whole body X-ray along with X-ray based focal beam and cesium-based cabinet irradiation in small animals to support tumor-based studies, including:
Our laboratories can deliver radiation doses to subcutaneous and orthotopic tumors with minimal surrounding tissue toxicity. We provide study design, execution, and analysis services to support major applications using this technology, including immunotherapy potentiation and radiosensitizers.
Invicro’s Image Analysis team provides comprehensive analysis services to solve complex problems in radiology and pathology. Our team of over fifty medical image processing scientists, including more than twenty Ph.D.s is responsible for extracting scientific quantitative data in support of Invicro’s studies from discovery research through late-phase clinical trials.
Our team blends cutting-edge image science with image engineering to continuously create and deploy novel algorithms and analysis pipelines, while also developing those methods into robust, efficient automated tools. Machine learning and deep learning are two powerful tools routinely used to drive these solutions. These methods are coupled with Invicro’s deep scientific domain knowledge to produce unique, custom solutions to a variety of tasks, spanning therapeutic area and modalities. We provide analysis services from a wide-range of modalities, including:
IPACS® is an innovative, next generation, web-based research content management and orchestration platform that has been built for image data science applications, including radiology and pathology. With the newest release, the modernization of the platform’s architecture provides users the flexibility to implement manual, semi-automated, and automated workflows to streamline imaging research workflows spanning preclinical and clinical studies. With its flexible hosting strategy and containerized capabilities, users will be able to deploy robust data solutions for a wide-range of applications.
Invicro - Imaging and Pathology Services has not received any reviews.
Invicro - Imaging and Pathology Services has not received any endorsements.